Aileron Therapeutics Stock Price, News & Analysis (NASDAQ:ALRN)

$9.69 -0.02 (-0.21 %)
(As of 01/16/2018 08:40 AM ET)
Previous Close$9.71
Today's Range$9.65 - $10.00
52-Week Range$8.77 - $15.48
Volume15,200 shs
Average Volume31,800 shs
Market Capitalization$142.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics logoAileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.

Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALRN
CUSIPN/A
Phone617-995-0900

Debt

Debt-to-Equity RatioN/A
Current Ratio11.58%
Quick Ratio11.58%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees15
Outstanding Shares14,720,000

Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics Inc (NASDAQ:ALRN) announced its earnings results on Thursday, November, 9th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.07. View Aileron Therapeutics' Earnings History.

Where is Aileron Therapeutics' stock going? Where will Aileron Therapeutics' stock price be in 2018?

4 equities research analysts have issued twelve-month price targets for Aileron Therapeutics' shares. Their forecasts range from $19.00 to $20.00. On average, they anticipate Aileron Therapeutics' share price to reach $19.33 in the next twelve months. View Analyst Ratings for Aileron Therapeutics.

Who are some of Aileron Therapeutics' key competitors?

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the folowing people:

  • Joseph A. Yanchik III, Esq., President, Chief Executive Officer, Director (Age 52)
  • Evan Lippman, Chief Financial Officer and Business Officer, Senior Vice President
  • Manuel C. Aivado, Senior Vice President and Chief Medical Officer
  • D. Allen Annis Ph.D., Vice President - Biophysical and Analytical Technologies
  • Seth L. Harrison M.D., Director (Age 56)

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

When did Aileron Therapeutics' lock-up period expire?

Aileron Therapeutics' lock-up period expired on Tuesday, December 26th. Aileron Therapeutics had issued 3,750,000 shares in its IPO on June 29th. The total size of the offering was $56,250,000 based on an initial share price of $15.00. Since the end of Aileron Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

How do I buy Aileron Therapeutics stock?

Shares of Aileron Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aileron Therapeutics' stock price today?

One share of Aileron Therapeutics stock can currently be purchased for approximately $9.69.

How big of a company is Aileron Therapeutics?

Aileron Therapeutics has a market capitalization of $142.63 million. Aileron Therapeutics employs 15 workers across the globe.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 281 ALBANY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-995-0900 or via email at [email protected]


MarketBeat Community Rating for Aileron Therapeutics (ALRN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aileron Therapeutics (NASDAQ:ALRN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.33$19.33$19.33N/A
Price Target Upside: 57.82% upside57.82% upside57.82% upsideN/A

Aileron Therapeutics (NASDAQ:ALRN) Consensus Price Target History

Price Target History for Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics (NASDAQ:ALRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2017Canaccord GenuityReiterated RatingBuy$19.00LowView Rating Details
7/24/2017William BlairInitiated CoverageOutperform -> OutperformHighView Rating Details
7/24/2017Bank of AmericaInitiated CoverageBuy -> Buy$19.00HighView Rating Details
7/24/2017Jefferies GroupInitiated CoverageBuy -> Buy$20.00HighView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Aileron Therapeutics (NASDAQ:ALRN) Earnings History and Estimates Chart

Earnings by Quarter for Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics (NASDAQ ALRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.36)($0.43)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.43)($0.45)ViewN/AView Earnings Details
2/8/2013Q3 2012($0.07)ViewN/AView Earnings Details
11/12/2012Q312($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aileron Therapeutics (NASDAQ:ALRN) Earnings Estimates

2018 EPS Consensus Estimate: ($2.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.49)($0.49)($0.49)
Q2 20181($0.57)($0.57)($0.57)
Q3 20181($0.61)($0.61)($0.61)
Q4 20181($0.69)($0.69)($0.69)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Aileron Therapeutics (NASDAQ:ALRN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aileron Therapeutics (NASDAQ ALRN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 7.64%
Insider Trades by Quarter for Aileron Therapeutics (NASDAQ:ALRN)
Institutional Ownership by Quarter for Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics (NASDAQ ALRN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2018Apple Tree Partners Ii LpMajor ShareholderSell150,000$9.80$1,470,000.00View SEC Filing  
7/5/2017Cvf, LlcMajor ShareholderBuy180,000$15.00$2,700,000.00View SEC Filing  
7/5/2017Lilly Ventures Fund I LlcInsiderBuy250,000$15.00$3,750,000.00View SEC Filing  
7/5/2017Reinhard J AmbrosDirectorBuy266,667$15.00$4,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aileron Therapeutics (NASDAQ ALRN) News Headlines

Source:
DateHeadline
 Aileron Therapeutics Inc (ALRN) Given $19.33 Consensus Target Price by Analysts Aileron Therapeutics Inc (ALRN) Given $19.33 Consensus Target Price by Analysts
www.americanbankingnews.com - January 13 at 1:58 PM
 Brokerages Expect Aileron Therapeutics Inc (ALRN) to Post -$0.46 EPS Brokerages Expect Aileron Therapeutics Inc (ALRN) to Post -$0.46 EPS
www.americanbankingnews.com - January 13 at 3:28 AM
Insider Selling: Aileron Therapeutics Inc (ALRN) Major Shareholder Sells 150,000 Shares of StockInsider Selling: Aileron Therapeutics Inc (ALRN) Major Shareholder Sells 150,000 Shares of Stock
www.americanbankingnews.com - January 11 at 6:38 PM
Aileron Therapeutics (ALRN) Lifted to Hold at Zacks Investment ResearchAileron Therapeutics (ALRN) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - January 10 at 5:26 PM
Zacks: Aileron Therapeutics Inc (ALRN) Given Average Rating of "Strong Buy" by BrokeragesZacks: Aileron Therapeutics Inc (ALRN) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 28 at 1:38 AM
Critical Analysis: Aileron Therapeutics (ALRN) versus The CompetitionCritical Analysis: Aileron Therapeutics (ALRN) versus The Competition
www.americanbankingnews.com - December 25 at 7:29 PM
Aileron Therapeutics Incs Lock-Up Period To End  on December 26th (NASDAQ:ALRN)Aileron Therapeutics Inc's Lock-Up Period To End on December 26th (NASDAQ:ALRN)
www.americanbankingnews.com - December 19 at 1:14 AM
 Analysts Set $19.33 Price Target for Aileron Therapeutics Inc (ALRN) Analysts Set $19.33 Price Target for Aileron Therapeutics Inc (ALRN)
www.americanbankingnews.com - December 13 at 7:54 AM
Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology MeetingAileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
finance.yahoo.com - December 11 at 6:02 PM
Zacks: Aileron Therapeutics, Inc. (ALRN) Receives Average Rating of "Strong Buy" from AnalystsZacks: Aileron Therapeutics, Inc. (ALRN) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - December 5 at 1:36 AM
 Aileron Therapeutics, Inc. (ALRN) Given Consensus Rating of "Strong Buy" by Analysts Aileron Therapeutics, Inc. (ALRN) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - November 19 at 1:38 PM
Aileron Therapeutics Is Now Oversold (ALRN)Aileron Therapeutics Is Now Oversold (ALRN)
www.thestreet.com - November 16 at 11:03 AM
Zacks: Brokerages Set $19.33 Price Target for Aileron Therapeutics, Inc. (ALRN)Zacks: Brokerages Set $19.33 Price Target for Aileron Therapeutics, Inc. (ALRN)
www.americanbankingnews.com - November 15 at 5:08 AM
Research Analysts Issue Forecasts for Aileron Therapeutics, Inc.s Q1 2018 Earnings (ALRN)Research Analysts Issue Forecasts for Aileron Therapeutics, Inc.'s Q1 2018 Earnings (ALRN)
www.americanbankingnews.com - November 13 at 6:00 AM
William Blair Comments on Aileron Therapeutics, Inc.s Q1 2018 Earnings (ALRN)William Blair Comments on Aileron Therapeutics, Inc.'s Q1 2018 Earnings (ALRN)
www.americanbankingnews.com - November 13 at 6:00 AM
Aileron Therapeutics (ALRN) Announces Oral Presentations on Lead Product Candidate ALRN-6924 at ASHAileron Therapeutics (ALRN) Announces Oral Presentations on Lead Product Candidate ALRN-6924 at ASH
www.streetinsider.com - November 2 at 2:16 AM
 Aileron Therapeutics, Inc. (ALRN) Given $19.33 Consensus Target Price by Analysts Aileron Therapeutics, Inc. (ALRN) Given $19.33 Consensus Target Price by Analysts
www.americanbankingnews.com - October 31 at 5:38 PM
Zacks: Analysts Set $19.33 Target Price for Aileron Therapeutics, Inc. (ALRN)Zacks: Analysts Set $19.33 Target Price for Aileron Therapeutics, Inc. (ALRN)
www.americanbankingnews.com - October 16 at 12:52 PM
Boston biotech developing obesity drug pulls down $120M in IPOBoston biotech developing obesity drug pulls down $120M in IPO
finance.yahoo.com - October 10 at 2:53 AM
Zacks: Aileron Therapeutics, Inc. (ALRN) Given $19.33 Average Price Target by BrokeragesZacks: Aileron Therapeutics, Inc. (ALRN) Given $19.33 Average Price Target by Brokerages
www.americanbankingnews.com - October 7 at 6:50 PM
Aileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap IndexesAileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap Indexes
finance.yahoo.com - September 19 at 3:46 PM
 Analysts Set $19.33 Target Price for Aileron Therapeutics Inc (ALRN) Analysts Set $19.33 Target Price for Aileron Therapeutics Inc (ALRN)
www.americanbankingnews.com - September 18 at 6:38 PM
TTOO Rallies For 2nd Day, SAGEs STATUS Flops, ICPT Warns Of Ocaliva OverdosingTTOO Rallies For 2nd Day, SAGE's STATUS Flops, ICPT Warns Of Ocaliva Overdosing
www.nasdaq.com - September 13 at 4:56 PM
 Aileron Therapeutics, Inc. (ALRN) Receives Average Recommendation of "Strong Buy" from Brokerages Aileron Therapeutics, Inc. (ALRN) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - September 11 at 8:36 PM
 Aileron Therapeutics, Inc. (ALRN) Given Consensus Rating of "Strong Buy" by Brokerages Aileron Therapeutics, Inc. (ALRN) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - September 2 at 12:36 PM
Aileron Therapeutics (ALRN) Announces Presentation of Preclinical Data with ALRN-6924 at ISEHAileron Therapeutics (ALRN) Announces Presentation of Preclinical Data with ALRN-6924 at ISEH
www.streetinsider.com - August 25 at 1:33 AM
Aduro Biotech (ADRO) and AILERON THERAP (ALRN) Head-To-Head AnalysisAduro Biotech (ADRO) and AILERON THERAP (ALRN) Head-To-Head Analysis
www.americanbankingnews.com - August 21 at 10:26 AM
Aileron Therap (ALRN) Stock Rating Reaffirmed by Canaccord GenuityAileron Therap (ALRN) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - August 11 at 6:20 PM
Aileron Therapeutics Reports Second Quarter 2017 Financial ResultsAileron Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 5:10 PM
Aileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth ConferenceAileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 4:45 PM
AILERON THERAPs (NASDAQ:ALRN) Quiet Period Will Expire  on August 8thAILERON THERAP's (NASDAQ:ALRN) Quiet Period Will Expire on August 8th
www.americanbankingnews.com - August 1 at 12:28 PM
Aileron Therap (ALRN) Expected to Post Earnings of -$0.43 Per ShareAileron Therap (ALRN) Expected to Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - July 31 at 6:32 PM
Equities Analysts Set Expectations for Aileron Theraps Q2 2017 Earnings (NASDAQ:ALRN)Equities Analysts Set Expectations for Aileron Therap's Q2 2017 Earnings (NASDAQ:ALRN)
www.americanbankingnews.com - July 26 at 9:25 AM
Research Analysts Offer Predictions for Aileron Theraps Q2 2017 Earnings (ALRN)Research Analysts Offer Predictions for Aileron Therap's Q2 2017 Earnings (ALRN)
www.americanbankingnews.com - July 26 at 9:24 AM
Aileron Therap (NASDAQ:ALRN) Earns Outperform Rating from Analysts at William BlairAileron Therap (NASDAQ:ALRN) Earns Outperform Rating from Analysts at William Blair
www.americanbankingnews.com - July 24 at 11:01 AM
[$$] Novartis, Glaxo and Lilly Bigly Back New Biotech[$$] Novartis, Glaxo and Lilly Bigly Back New Biotech
finance.yahoo.com - July 19 at 4:55 PM
Aileron Therap (NASDAQ:ALRN) Insider Lilly Ventures Fund I. Llc Acquires 250,000 SharesAileron Therap (NASDAQ:ALRN) Insider Lilly Ventures Fund I. Llc Acquires 250,000 Shares
www.americanbankingnews.com - July 7 at 10:42 PM
Aileron Therapeutics Announces Pricing of Initial Public OfferingAileron Therapeutics Announces Pricing of Initial Public Offering
finance.yahoo.com - July 7 at 5:28 AM
Heres the Latest on Four New Biotech IPOsHere's the Latest on Four New Biotech IPOs
finance.yahoo.com - July 7 at 5:28 AM
Aileron Therapeutics Inc (ALRN) Director Buys $4,000,005.00 in StockAileron Therapeutics Inc (ALRN) Director Buys $4,000,005.00 in Stock
www.americanbankingnews.com - July 5 at 10:24 PM
Aileron Therapeutics Inc (ALRN) Major Shareholder Acquires $2,700,000.00 in StockAileron Therapeutics Inc (ALRN) Major Shareholder Acquires $2,700,000.00 in Stock
www.americanbankingnews.com - July 5 at 10:22 PM

SEC Filings

Aileron Therapeutics (NASDAQ:ALRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aileron Therapeutics (NASDAQ:ALRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aileron Therapeutics (NASDAQ ALRN) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.